Honing Clinical Skills in HIV Treatment - Module 3

Faculty

Eric S. Daar, MD (Moderator)
Chief of the Division of HIV Medicine
Harbor-University of California, Los Angeles (UCLA) Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

José R. Arribas, MD
Head, Infectious Diseases Unit
Research Director of HIV and Infectious Diseases
La Paz Hospital
Associate Professor of Medicine
Autonoma University School of Medicine
Madrid, Spain

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Georgetown University
Infectious Disease Physician
Unity Health Care
Washington, District of Columbia

Aadia Rana, MD
Associate Professor of Medicine
University of Alabama-Birmingham
Associate Scientist
UAB Center for AIDS Research
Birmingham, Alabama

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Program Description

This activity is the third of a 3-part series based on the proceedings of a CME symposium held in conjunction with IAS 2021. This activity covers treatment selection and emerging options for heavily treatment-resistant patients and Dr. Eric Daar discusses clinical trial data and considerations for long-acting injectables. To view the full content from the symposium, please participate in the other modules in this series. In Module 1, Dr. Eric Daar reviews the science behind treatment strategies, such as rapid antiretroviral therapy (ART), 2-drug oral and long-acting regimens, and emerging ART options. In Module 2, Dr. Aadia Rana discusses the evidence behind and implementation of rapid ART, both in the United States and globally, and Dr. Seble Kassaye discusses tailoring ART in aging patients with comorbidities and the relationship between ART and weight gain.

Educational Objectives

After completing this activity, the participant should be better able to:

• Describe the science behind recent advances in HIV treatment
• Implement appropriate workflow protocols to optimize rapid ART implementation
• Tailor ART regimens according to patient comorbidities, risk factors, polypharmacy, viral level, and treatment history

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

PIM designates part 3 of this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for part 3 of this Continuing Nursing Education activity is 0.5 contact hours.

Disclosure of Conflicts of Interest

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.

PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

Eric S. Daar, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited

José R. Arribas, MD: Consulting Fees: Alexza Pharmaceuticals, Eli Lilly and Company, EMD Serono, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Teva Pharmaceuticals USA, Inc., ViiV Healthcare Limited; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp, ViiV Healthcare Limited; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare Limited

Seble G. Kassaye, MD, MS: Nothing to disclose

Aadia Rana, MD: Nothing to disclose

Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Instructions to Receive Credit

In order to receive credit, participants must score at least 75% on the posttest and complete the program evaluation. 

CME Questions – PIM Contact Information

For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information

For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.